Clinical Trials Logo

ECT clinical trials

View clinical trials related to ECT.

Filter by:

NCT ID: NCT02500225 Completed - Anesthesia Clinical Trials

Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy

Start date: January 2017
Phase: Phase 4
Study type: Interventional

The purpose of the study was to investigate the effects of etomidate or sevoflurane used in electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and recovery profiles.

NCT ID: NCT01905904 Completed - Anesthesia Clinical Trials

Sevoflurane in Electroconvulsive Therapy

Start date: March 2013
Phase: Phase 4
Study type: Interventional

The purpose of the study was to investigate the effects of different doses of sevoflurane used in electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and recovery profiles

NCT ID: NCT01441960 Completed - Clinical trials for Neuromuscular Blockade

Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)

Start date: May 2011
Phase: N/A
Study type: Interventional

Electroconvulsive therapy (ECT) is the transcutaneous application of small electrical stimuli to the brain to produce generalized seizures for the treatment of selected psychiatric disorders such as severe depression. The aim of ECT is to induce a therapeutic tonic seizure where the person loses consciousness and has convulsions. Patients need general anesthesia and neuromuscular blockade to treat pain and avoid excessive tonic clonic motor contraction that might be associated with compression fractures. Neuromuscular blocking drugs (NMBD) are, therefore, administered after induction of general anesthesia to induce neuromuscular blockade. Despite the importance of NMBDs to provide optimal conditions for ECT treatment, the optimal NMBD dose to achieve acceptable neuromuscular blockade without excessive or untoward effects has not previously been identified in any study and in a prospective randomized fashion. The aim of this study is, therefore, to identify the optimal NMBD dose of two commonly used neuromuscular blocking agents (succinylcholine and rocuronium) in order to optimize the muscle strength modulation during ECT that facilitates ECT with the minimal side effects.

NCT ID: NCT01047371 Completed - Pain Clinical Trials

Why in Hospital - Factors Determining Time to Discharge Readiness After Arthroplasty Surgery

Start date: January 2010
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate patient related factors determining length of stay in hospital after arthroplasty surgery.